Novo Nordisk has garnered its first global approval for its once-weekly diabetes therapy Ozempic in the US.
News
Time is running out – Enter Now!
The deadline for completed multiple choice questionnaires (MCQ’s – Stage 1 of the competition) and essays (Stage 2, otherwise known as the ‘Clinical Challenge’) is 31 January and with the festive season approaching, it’s sure to come round much faster than you think.
Just how strong is your team?
The PharmaTimes Clinical Researcher of the Year competition is looking for the best clinical teams in the Americas. Is yours one of them? If so, you need to enter now!
Lilly’s Taltz cleared to treat psoriatic arthritis
US regulators have expanded the scope of Eli Lilly’s plaque psoriasis drug Taltz to include the treatment patients with psoriatic arthritis.
AZ’ Tudorza hits study goals in COPD patients with CV risk factors
AstraZeneca says top-line results from a post-marketing study show that Tudorza Pressair is effective in reducing chronic obstructive pulmonary disease (COPD) exacerbations in patients with cardiovascular issues.
MSD, Wayra UK launch third Velocity Health programme
Merck Sharp & Dohme and Telefonica’s Wayra UK have unveiled the next focus of their digital health innovation accelerator programme, calling on tech start-ups to “re-imagine healthcare” with the help of artificial intelligence and machine learning.
AbbVie’s IL-23 blocker shows efficacy in psoriasis trial
An experimental therapy being developed by AbbVie for the treatment of patients with moderate to severe plaque psoriasis has hit key targets in a pivotal late-stage trial.
New data shows rise in access to NHS talking therapies
More than one million referrals were made in 2016 to NHS talking therapies for depression and anxiety, according to new data from NHS Digital.
US approves first Herceptin biosimilar
Mylan and Biocon’s Ogivri is the first biosimilar of Herceptin to win US approval, for certain breast cancer and metastatic stomach cancers.
Sanofi ends development of Clostridium difficile vaccine
Sanofi has pulled the plug on its experimental Clostridium difficile vaccine after an interim analysis of a late-stage trial concluded that key targets were unlikely to be met.
NHS A&E performance target remains well under par
December has kicked off with NHS hospital performance against the four hour A&E target standing at just 82.45 percent – 12.55 percentage points lower than the 95 percent standard, reports the Royal College of Emergency Medicine (RCEM).
Inhaled heparin shows potential in lung disease
The veteran bloodthinner heparin has been found in a small UK trial to help improve breathing when inhaled by patients with chronic obstructive pulmonary disease (COPD).
FDA approves heart protection label change for Repatha
US regulators have approved Amgen’s Repatha as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularisations in adults with cardiovascular disease.
Orphan status for Shire’s experimental UC drug
US regulators have granted Shire’s investigational therapy SHP647 orphan status for the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC).
Pfizer’s Somavert to be funded by NHS Wales
Pfizer’s Somavert will be funded by NHS Wales as a treatment for eligible, adult patients with acromegaly in the third-line setting.
